Aaron Gerds, MD: Glasdegib and New Directions in Myelofibrosis Treatment

• Date :
• 1    
  0

Promising Cardiac and Renal Responses with NEOD001 in Patients with AL Amyloidosis

• Date :
• 1    
  0

Robert Kreitman: Delayed Versus Concurrent Rituximab in Hairy Cell Leukemia

• Date :
• 0    
  0

Tibor Kovacsovics: CX-01 Associated With High Response Rates in Older Patients With AML

• Date :
• 0    
  0

Paul Richardson: Isatuximab Improves PFS in Relapsed/Refractory Myeloma

• Date :
• 0    
  0

Iman Abou Dalle: Leuprolide Improves Post-Chemotherapy Recovery

• Date :
• 0    
  0

Naveen Pemmaraju: A New Option for Myelofibrosis?

• Date :
• 0    
  0

David Sallman: Early Results of 5F9 in AML and MDS

• Date :
• 0    
  0

Catherine Diefenbach: Polatuzumab Vedotin for Follicular Lymphoma

• Date :
• 0    
  0

Irene Ghobrial: Preventing Progression from Smoldering to Symptomatic Myeloma

• Date :
• 0    
  0

Alok Khorana: Rivaroxaban Prevents Cancer-Associated VTE

• Date :
• 0    
  0

Austin Kulasekararaj: A New Treatment Option for PNH?

• Date :
• 0    
  0

Erik Serrao: A Rapid Screening Test for Sickle Cell Disease

• Date :
• 0    
  0

Alan List: Is Luspatercept a New Option for Patients With MDS?

• Date :
• 0    
  0

Aziz Nazha: A Personalized Prediction Model for MDS

• Date :
• 0    
  0

Michael Kovacs: LMWH Bridging for Patients at High Risk for Arterial Thromboembolism

• Date :
• 0    
  0

Luciano Costa: Evaluating a Venetoclax and Carfilzomib Combination in Myeloma

• Date :
• 0    
  0

Farhad Ravandi-Kashani: AMG 330 Takes a BiTE out of Relapsed/Refractory AML

• Date :
• 0    
  0

Jennifer Woyach: Ibrutinib Outperforms Chemoimmunotherapy in CLL

• Date :
• 0    
  0

Luc-Matthieu Fornecker, MD, PhD: Risks and Benefits of BV + AVD in Treatment-Naive Hodgkin Lymphoma

• Date :
• 0    
  0

Stephen J. Schuster, MD: Tisagenlecleucel Promising in Relapsed/Refractory DLBCL

• Date :
• 0    
  0

Yazan F. Madanat, MD: How Does Smoking Increase MDS Risk?

• Date :
• 0    
  0

James N. Kochenderfer, MD: Advancing CAR T-Cell Therapy for Myeloma

• Date :
• 0    
  0

Jeanette K. Doorduijn, MD, PhD, and Samar Issa, MD: Does Rituximab Improve Survival in CNS Lymphoma?

• Date :
• 0    
  0

Prithviraj Bose, MD: Optimizing Ruxolitinib With Sotatercept for Myelofibrosis

• Date :
• 0    
  0

Gerald A. Soff, MD: Examining a New Indication for Romiplostim

• Date :
• 0    
  0

Joseph Connors, MD: Bleomycin or Brentuximab Vedotin in Hodgkin Lymphoma?

• Date :
• 0    
  0

Daniel DeAngelo, MD, PhD: BLU-285 Active, Well-Tolerated in Advanced Systemic Mastocytosis

• Date :
• 0    
  0

Remco Molenaar, MD, PhD: TET2 Mutations Predict Cardiovascular Risk in MDS and CMML

• Date :
• 0    
  0

Mikkael A. Sekeres, MD, MS: Highlights of the 2017 ASH Annual Meeting

• Date :
• 0    
  0

Samir K. Ballas, MD: Sickle Cell Patients Are Innocent Victims of the Opioid Epidemic

• Date :
• 0    
  0

Eytan M. Stein, MD: Enasidenib Shows "Encouraging" Efficacy in IDH2-Mutated AML

• Date :
• 0    
  0

Jae Hong Park, MD: Improving Outcomes, Minimizing Toxicity With CAR T-Cell Therapy in B-Cell ALL

• Date :
• 0    
  0

Frederick Locke, MD: CAR T-Cell Therapy in Relapsed/Refractory NHL

• Date :
• 0    
  0

Mathias Rummel, MD, PhD: Bendamustine-Rituximab "StiL" Beats R-CHOP for Indolent Lymphomas

• Date :
• 0    
  0

Saar Gill, MD: Combining CAR T-Cell Therapy With Ibrutinib in CLL Patients

• Date :
• 0    
  0

Nicholas J. Short, MD: Inotuzumab Plus Lower-Intensity Chemotherapy in Older Patients with ALL

• Date :
• 0    
  0

Jeff P. Sharman, MD: Ublituximab Plus Ibrutinib Improves Response Rate in High-Risk CLL

• Date :
• 0    
  0

Ruben Mesa, MD: Momelotinib Non-Inferior to Ruxolitinib in Myelofibrosis

• Date :
• 0    
  0

Richard Stone, MD: New FLT3 Inhibitor Crenolanib Shows Promise in FLT3-Mutated AML

• Date :
• 0    
  0

Noopur Raje, MD: Denosumab Versus ZA for Myeloma-Related Bone Disease

• Date :
• 0    
  0

Ian Flinn, MD: Bendamustine Plus Rituxmab Outperforms R-CHOP In Long-Term BRIGHT Follow-up

• Date :
• 0    
  0

Eugenia Vicky Asare, MD: Multidisciplinary Care Saves Lives Among Pregnant Women with SCD in Ghana

• Date :
• 0    
  0

Kenneth Ataga, MD: Crizanlizumab: A New Option for Managing Sickle Cell-Related Pain Crises?

• Date :
• 0    
  0

Adam D. Cohen, MD: Expanding CAR T Cells to Treat Myeloma

• Date :
• 0    
  0

Graham Jackson, MD: Lenalidomide Maintenance Is Effective in All Types of Myeloma Patients

• Date :
• 0    
  0

Crystal Mackall, MD: Passing the Checkpoint With New Approaches to Immunotherapy

• Date :
• 0    
  0

Alexander Perl, MD: The New FLT3 Inhibitor Gilteritinib is “Well-Tolerated” in AML

• Date :
• 0    
  0

Steven Pipe, MD: Changing the Delivery of Bleeding Prevention for Hemophilia Patients

• Date :
• 0    
  0

Sherrill J. Schlicter, MD: Prolonging Platelet Shelf-Life With DMSO

• Date :
• 0    
  0

Not Just CRISPR: Changing Biology Through Gene-Editing

• Date :
• 0    
  0

Sattva S. Neelapu, MD: Encouraging Results for CAR T-Cells in Refractory DLBCL

• Date :
• 0    
  0

Robert E. Marcus, MD: GALLIUM Study of Obinutuzumab in Untreated Follicular Lymphoma

• Date :
• 0    
  0

David Miklos, MD, PhD: Ibrutinib in Chronic Graft-Versus-Host Disease

• Date :
• 0    
  0

John Mascarenhas, MD, MS: Continuing to Evaluate Pacritinib for Myelofibrosis

• Date :
• 0    
  0

Anjali Advani, MD: Vadastuximab Talirine in Treatment-Naïve CD33-Positive AML

• Date :
• 0    
  0

Joan C. Gill, MD: New Recombinant Factors for von Willebrand Disease

• Date :
• 0    
  0

Dan T. Vogl, MD: Selinexor Plus Low-Dose Dexamethasone in “Penta-Refractory” Myeloma Patients

• Date :
• 0    
  0

Martin Schrappe, MD: Attempting to Reduce Chemotherapy Burden in Children With ALL

• Date :
• 0    
  0

Stephen M. Ansell, MD, PhD: Nivolumab Moves to Hematology

• Date :
• 0    
  0

Ruben A. Mesa, MD: Treating Myelofibrosis After Ruxolitinib “Failure

• Date :
• 0    
  0

Melissa A. Crawley, MD: How Can We Enroll More Young Patients in Clinical Trials?

• Date :
• 0    
  0

Jennifer R. Brown, MD, PhD: Ibrutinib and Atrial Fibrillation Risk in RCTs

• Date :
• 0    
  0

Aziz Nazha, MD: How Do TP53 Mutation Characteristics Affect MDS Outcomes?

• Date :
• 0    
  0

Jonathan Friedberg, MD: Treating Highly Aggressive Lymphomas

• Date :
• 0    
  0

Joseph M. Connors, MD: Optimizing Therapy, Minimizing Toxicity in Hodgkin Lymphoma

• Date :
• 0    
  0

Hetty Caraway, MD: Improving Classification in High-Grade MDS

• Date :
• 0    
  0

Bhagirathbhai Dholaria, MBBS: Overlapping Myeloma and CLL: Double Trouble?

• Date :
• 0    
  0

Jennifer R. Brown, MD, PhD: The Changing Definition of “High-Risk” CLL

• Date :
• 0    
  0

Mogamulizumab May Be Effective in Relapsed/Refractory T-Cell Leukemia

• Date :
• 0    
  0

Ixazomib Benefit Persists Despite Prior Therapy in TOURMALINE-MM1 Subset Analysis

• Date :
• 0    
  0

Venetoclax Plus Hypomethylating Agents Leads to High Response Rates in Older Patients with AML

• Date :
• 0    
  0

COMFORT: Five-Year Outcomes of Ruxolitinib in Patients With Myelofibrosis

• Date :
• 0    
  0

CPX-351: A Potential Game-Changer for Older Patients With Newly Diagnosed Secondary AML?

• Date :
• 0    
  0

Study Finds Thrombosis Risk Changes Throughout Myeloma Disease Course

• Date :
• 0    
  0

SL-401: An Encouraging Option for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm

• Date :
• 0    
  0

CASTOR Trial: Daratumumab Combination Doubles Response Rates in Myeloma Patients

• Date :
• 0    
  0

TOURMALINE-MM3 and 4: Ixazomib as Maintenance Therapy in Myeloma Patients

• Date :
• 0    
  0

For Older AML Patients, Venetoclax With Low-Dose Cytarabine is Safe and “Promising

• Date :
• 0    
  0

Bortezomib Leads to More Complete Remissions in Patients With High-Risk Follicular Lymphoma

• Date :
• 0    
  0

Ixazomib Plus Pomalidomide, Dexamethasone in Relapsed/Refractory Myeloma

• Date :
• 0    
  0

Optimizing CAR T-Cell Therapy in Relapsed/Refractory ALL

• Date :
• 0    
  0

Is Rivaroxaban Safe as Long-Term Prevention for Deep-Vein Thrombosis?

• Date :
• 0    
  0

Multiple Advances in Multiple Myeloma

• Date :
• 0    
  0

Rivaroxaban in Cancer-Associated VTE: Results from CALLISTO

• Date :
• 0    
  0

The Balancing Act of Caring for Older Patients with Hemophilia

• Date :
• 0    
  0

Late-Breaking Abstract: RESONATE 2 Finds First-Line Ibrutinib Superior to Chlorambucil in CLL/SLL

• Date :
• 0    
  0

Ibrutinib Beats Temsirolimus in Relapsed/Refractory MCL

• Date :
• 0    
  0

Improving Quality of VTE Care

• Date :
• 0    
  0

The PROs of Patient-Reported Outcomes

• Date :
• 0    
  0

Induction Chemotherapy for AML: Understanding the Patient Experience

• Date :
• 0    
  0

Late-Breaking Abstract: First-in-Man Trial of CAR T Cells in Myeloma

• Date :
• 0    
  0

Ixazomib Extends PFS in the TOURMALINE-MM1 Trial

• Date :
• 0    
  0

Evolving Issues in Anticoagulation

• Date :
• 0    
  0

Predicting Prognosis in Myelodysplastic Syndromes

• Date :
• 0    
  0

New Approaches in CLL and Prolymphocytic Leukemia

• Date :
• 0    
  0

Late-Breaking Abstract: Eltrombopag Improves Response in Severe Aplastic Anemia

• Date :
• 0    
  0

Optimizing Therapy in Sickle Cell Disease

• Date :
• 0    
  0

Controversy over Quality

• Date :
• 0    
  0

Eligibility Criteria Not Associated with Adverse Events in RCTs

• Date :
• 0    
  0

Newly Approved Drugs: How Should Do We Use Them in the Clinic?

• Date :
• 0    
  0

Ibrutinib + Bendamustine/Rituximab in Patients with Previously Treated CLL/SLL

• Date :
• 0    
  0

Is the Combo of Abbreviated Chemo Plus Radiation Therapy a Viable Option for DLBCL Patients?

• Date :
• 0    
  0

Collaborative Care Delivery Reduces Travel Burden for AML Patients

• Date :
• 0    
  0

The Future of Clinical and Translational Research in Hematologic Malignancies

• Date :
• 0    
  0

Ksenia Romanova, MD: Age, Sex, Timing of Treatment Predict Avascular Necroses in Children with ALL

• Date :
• 0    
  0

Brad Schenkel, MSc: Predicting Hospitalizations, ER Visits Among CLL Patients

• Date :
• 0    
  0

Daratumumab Safe in Relapsed/Refractory Multiple Myeloma Patients

• Date :
• 0    
  0

ASP2215 Successfully Inhibits FLT3 in High-Risk AML Patients

• Date :
• 0    
  0

New Biomarkers and Prognostic Indicators in Leukemia and MDS

• Date :
• 0    
  0

SIRIUS: Promising Results for Daratumumab in Hard-to-Treat Myeloma Patients

• Date :
• 0    
  0

Brentuximab Vedotin Plus AVD: Limiting Toxicity in Limited-Stage Hodgkin Lymphoma

• Date :
• 0    
  0

Obinutuzumab Extends Remission Time in Rituximab-Refractory iNHL

• Date :
• 0    
  0

CLL-IPI: A New and Improved Staging System for CLL?

• Date :
• 0    
  0

Ruxolitinib in CMML: Study Shows Promising Results

• Date :
• 0    
  0

PERSIST-1: Pacritinib Shakes Up the Current Myelofibrosis Treatment Landscape

• Date :
• 0    
  0

Complete Response at 30 Months: A Surrogate for PFS in First-Line Follicular Lymphoma

• Date :
• 0    
  0

Options for Treating the High-Risk APL Patient

• Date :
• 0    
  0

9ème Journée Nationale Maladies Rares Immuno-Hématologiques - MaRIH 2023

• Date :
• 3380    
  6

International Society on Thrombosis and Haemostasis congress - ISTH 2023

• Date :
• 4963    
  0

The European Hematology Association - EHA 2023

• Date :
• 8092    
  0

MDS - 17th International Congress on Myelodysplastic Syndromes

• Date :
• 12637    
  0

43e congrès annuel de la Société Française d’Hématologie - SFH 2023

• Date :
• 9346    
  7